Ventus Therapeutics Initiates Clinical Testing of VENT|03

NNC-6022-0001 - Drug Targets, Indications, Patents - Synapse

About Ventus Therapeutics Ventus Therapeutics is a clinical-stage ... ” Ventus expects to initiate a Phase 1b trial of VENT-02 in patients with ...

Drug & Device Pipeline News - CenterWatch

Trials Initiated. Eilean Therapeutics, ZE46-0134, FLT3-mutated acute myeloid leukemia, Initiation of a phase 1 trial. Ventus Therapeutics, VENT- ...

Latest News from Inception Therapeutics

May 6, 2020. Ventus Therapeutics Launches with $60 Million Series A ... Tempest Therapeutics Starts Phase I/Ib Clinical Trial with First-in-Class PPAR Alpha ...

More Than Lupus - TUESDAY NEWSDAY! Ventus Therapeutics...

TUESDAY NEWSDAY! Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a phase 2 study...

Ventus to Advance cGAS Inhibitor as New Treatment for Lupus

... VENT-03 if it moves forward in clinical testing. Additional cGAS inhibitors from Ventus are also on the horizon. “Given the highly validated ...

Bioventus - Innovations For Active Healing

Restorative Therapies · Surgical Solutions · Patients · Physicians · Investigator Initiated Study Request · Medical Education · payers · News · Careers ...

VENT-03 by Ventus Therapeutics for Neuroinflammation: Likelihood ...

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. VENT-03 ...

Ventus Therapeutics to Present Data for Novel Brain-Penetrant ...

... initiation, timing, progress and results of preclinical studies and clinical trials of its future product candidates; the results of Ventus ...

Ventyx Biosciences, Inc. FY'22 Annual Report

... VENT-05 (preclinical) from Ventus Therapeutics; and OLT-. 1177 (Phase ... Negative results in investigator-initiated clinical trials, regardless ...

Novo Nordisk doses first subject in Phase I trial of NLRP3 inhibitor

Ventus Therapeutics licenced NNC6022-0001 to Novo Nordisk in September 2022. ... “This trial initiation marks the first stage in our NLRP3 inhibitor clinical ...

UCB and Biogen Announce Positive Phase III Clinical Trial Results ...

UPDATE: Ventus Therapeutics Announces Positive Phase 1 Trial Results for Investigational Drug, VENT-03, for Lupus · News. GSK Set to Acquire ...

Novo Nordisk buys into NLRP3 program for potential $700m

The deal sees Novo Nordisk enter into a development and license agreement with Ventus Therapeutics for the latter's lead NLRP3 inhibitor, VENT-01.

tm2313083-12_s1a - block - 20.6196371s - SEC.gov

... studies and initiate clinical trials. In addition, if we obtain regulatory ... Ventus Therapeutics, Inc., a private biopharmaceutical company. She also ...

生物制药公司Ventus Therapeutics启动新型口服脑穿透性NLRP3抑制 ...

关联公司. 2023-08-22 Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor.

Screening NLRP3 drug candidates in clinical development - Frontiers

(Vent-01). Novo Nordisk. Safety. Oral. NCT06336005. Phase 1. NA. Vent-02. Ventus. Therapeutics. Safety. Oral. NA. Phase 1. NA. *announced; NA, ...

NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears Robust ...

In April 2024, Ventus Therapeutics announced results from its Phase I clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.

Ventus Therapeutics to Present Data on Novel cGAS Small ...

... clinical development,” said Michael ... Ventus' preclinical studies and anticipated therapeutic benefits of its future product candidates.

Gold Leaf Awards - BIOTECanada

Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying ... Ventus completed one of the highest value preclinical deals of 2022 for VENT ...

Montreal's Ventus Therapeutics strikes US$700-million-plus deal ...

... initiates an immune system response. NLRP3 can also overactivate ... Ventus to take the drugs in the deal through clinical trials. “We ...

Introducing Fierce Biotech's 2023 Fierce 15

The biotech also has three candidates in clinical trials, all in midstage development. The first program is testing bacteriophage therapies in ...